As of June 30, CalciMedica had approximately $19.1M in cash, cash equivalents and short-term investments, which, based on its current operating plan, CalciMedica expects to be sufficient to fund its operations into the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALC:
- CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
- CalciMedica price target raised to $20 from $14 at Oppenheimer
- CalciMedica enrolls first patient in trial of Auxora in acute kidney injury
- CalciMedica set to join Russell Microcap Index
- CalciMedica price target lowered to $15 from $22 at JonesResearch